Treatments for Acute Myeloid Leukemia

 Treatments for Acute Myeloid Leukemia

Drugs used to treat Acute Myeloid Leukemia

 

olutasidenib

Idamycin PFS

glasdegib

cytarabine liposomal / daunorubicin liposomal

ivosidenib

midostaurin

gemtuzumab

Daurismo

gilteritinib

enasidenib

Vyxeos

Onureg

Mylotarg

daunorubicin

Xospata

vincristine

Rydapt

idarubicin

decitabine

Tibsovo

Idhifa

azacitidine

venetoclax

Venclexta

cytarabine

Vanflyta

Rezlidhia

quizartinib

What is Acute Myeloid Leukemia?

 

Acute Myeloid Leukemia (AML) is an aggressive type of blood and bone marrow cancer that impacts the myeloid line of blood cells, which gives rise to various types of white blood cells, red blood cells, and platelets. It is classified as "acute" because it progresses quickly, often requiring prompt medical attention and aggressive treatment. AML is more common in adults, especially older adults, although it can occur at any age.

 

1. Pathophysiology

   - Origin: AML originates in the bone marrow, where abnormal (leukemic) cells rapidly proliferate and crowd out normal cells.

   - Mutations: It often involves genetic mutations, chromosomal abnormalities, or abnormal genes that prevent immature myeloid cells from developing into healthy blood cells.

   - Subtypes: The World Health Organization (WHO) classifies AML into different subtypes based on genetic mutations, molecular markers, and cellular features, which impact prognosis and treatment decisions.

 

2. Symptoms

   The rapid accumulation of abnormal white blood cells interferes with normal blood cell production, leading to:

   - Anemia: Fatigue, weakness, pale skin due to reduced red blood cells.

   - Neutropenia: Increased susceptibility to infections due to a decrease in normal white blood cells.

   - Thrombocytopenia: Bruising, bleeding gums, and small red spots on the skin (petechiae) due to low platelet counts.

   - Other symptoms: Fever, bone pain, weight loss, and night sweats are also common. In some cases, the liver or spleen may enlarge (hepatosplenomegaly).

 

3. Risk Factors

   - Age: Older age is a significant risk factor, as AML is more common in adults over 60.

   - Genetic predisposition: Some inherited genetic conditions, such as Down syndrome, are linked to AML.

   - Previous cancer treatments: Prior exposure to chemotherapy or radiation therapy increases risk.

   - Environmental exposure: Exposure to certain chemicals (e.g., benzene) and smoking have been linked to AML.

   - Other blood disorders: Conditions like myelodysplastic syndromes (MDS) and aplastic anemia may progress to AML.

 

4. Diagnosis

   - Blood tests: Complete blood count (CBC) may reveal anemia, leukocytosis, or thrombocytopenia.

   - Bone marrow biopsy: A sample of bone marrow is examined for the presence of leukemic cells, typically with more than 20% blast cells (immature white cells) confirming AML.

   - Cytogenetic and molecular testing: Identifies chromosomal abnormalities (e.g., FLT3, NPM1, CEBPA mutations) that help determine prognosis and treatment strategy.

 

5. Classification

   - French-American-British (FAB) System: Previously used system classifying AML based on cell morphology (M0-M7).

   - WHO Classification: Focuses on genetic and molecular abnormalities to classify AML into several subtypes, which can influence treatment decisions.

 

6. Treatment

   Treatment is often intensive, given AML's aggressive nature, and typically includes:

   - Induction chemotherapy: Initial phase aimed at achieving remission by eradicating leukemia cells.

   - Consolidation chemotherapy: Follow-up treatment to prevent relapse and eliminate any remaining leukemia cells.

   - Targeted therapies: Drugs like midostaurin and gilteritinib target specific genetic mutations (e.g., FLT3) in leukemic cells.

   - Stem cell transplantation (SCT): May be considered for eligible patients to replace diseased bone marrow with healthy stem cells.

   - Supportive care: Addressing side effects, infections, and complications related to AML or its treatments, such as blood transfusions and antibiotics.

 

7. Prognosis

   Prognosis depends on factors including age, overall health, subtype, and specific genetic mutations. Younger patients generally have a better outlook, while older patients face higher risks of treatment complications. AML with certain mutations, such as FLT3, is associated with a poorer prognosis, though new therapies targeting these mutations offer hope for improved outcomes.

 

8. Research and Advances

   - Molecular-targeted therapies: Research is ongoing for drugs that target genetic mutations, including FLT3, IDH1/IDH2, and BCL-2 inhibitors.

   - Immunotherapy: Novel approaches, such as CAR T-cell therapy, are being explored for AML, though challenges remain in adapting this technology effectively to AML.

 

Summary

AML is a complex and aggressive leukemia that affects the bone marrow’s ability to produce normal blood cells. Early diagnosis and intensive treatment are crucial. Advances in genetic research and targeted therapies are enhancing the treatment landscape, providing new hope for improved outcomes in AML.